COVID-19 morbidity and its influence on death rate in patients with pulmonary arterial and chronic thromboembolic pulmonary hypertension
Article Sidebar
This work is licensed under a Creative Commons Attribution 4.0 International License.
Main Article Content
https://orcid.org/0000-0002-4091-4910
Abstract
The aim – the COVID-19 pandemic influenced seriously on people life in all of the world, including patients with such hard-chronic diseases like pulmonary hypertensions. The aim of our study was to evaluate the COVID-19 morbidity and its influence on mortality during the first 13 pandemic months in patients with pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH).
Materials and methods. We provided the retrospective analysis of the patient data which were included in the center register before 31 March 2021. The evaluation of COVID-19 morbidity and mortality rate was done for the period between 01 March 2020 and 31 March 2021 (the period without active vaccination in Ukraine). The information about virus disease had to be confirmed by source documents.
Results and discussion. Till 31 March 2021 the data of 494 patients with PAH/CTEPH were included in the register. 75 (15.2 %) patients died. During the follow-up period 44 patients suffered from COVID-19 (10.2 % among all (n=433) who were alive at 01 March 2020 or included in register after 01 March 2020). The most patients (91 %) with COVID-19 had the pneumonia, but only 9 (20.5 %) were hospitalized and 4 (9.1 %) were moved to the intensive care unit and died. In general PAH/CTEPH cohort the mortality rate was 2.9 % during the first 13 months of the pandemic. It did not significant differ with mortality rates in previous years, except 2015 year when the mortality rate was 12.3 %.
Conclusion. The COVID-19 mortality was higher in pulmonary hypertensive patients in comparison with general Ukrainian population. But COVID-19 pandemic did not influence significantly on mortality rate in general PAH/CTEPH cohort during the first 13 pandemic months.
Article Details
Keywords:
References
Galiè N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, Ghofrani A, Gomez Sanchez MA, Hansmann G, Klepetko W, Lancellotti P, Matucci M, McDonagh T, Pierard LA, Trindade PT, Zompatori M, Hoeper M; ESC Scientific Document Group. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016 Jan 1;37(1):67-119. https://doi.org/10.1093/eurheartj/ehv317. Epub 2015 Aug 29. PMID: 26320113.
Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An evaluation of long-term survival from time of diagnosis in pulmonary arterial hypertension from the REVEAL Registry. Chest. 2012 Aug;142(2):448-56. https://doi.org/10.1378/chest.11-1460.
Broberg CS, Kovacs AH, Sadeghi S, Rosenbaum MS, Lewis MJ, Carazo MR, Rodriguez FH 3rd, Halpern DG, Feinberg J, Galilea FA, Baraona F, Cedars AM, Ko JM, Porayette P, Maldonado J, Sarubbi B, Fusco F, Frogoudaki AA, Nir A, Chaudhry A, John AS, Karbassi A, Hoskoppal AK, Frischhertz BP, Hendrickson B, Bouma BJ, Rodriguez-Monserrate CP, Broda CR, Tobler D, Gregg D, Martinez-Quintana E, Yeung E, Krieger EV, Ruperti-Repilado FJ, Giannakoulas G, Lui GK, Ephrem G, Singh HS, Almeneisi HM, Bartlett HL, Lindsay I, Grewal J, Nicolarsen J, Araujo JJ, Cramer JW, Bouchardy J, Al Najashi K, Ryan K, Alshawabkeh L, Andrade L, Ladouceur M, Schwerzmann M, Greutmann M, Meras P, Ferrero P, Dehghani P, Tung PP, Garcia-Orta R, Tompkins RO, Gendi SM, Cohen S, Klewer S, Hascoet S, Mohammadzadeh S, Upadhyay S, Fisher SD, Cook S, Cotts TB, Aboulhosn JA. COVID-19 in Adults With Congenital Heart Disease. J Am Coll Cardiol. 2021 Apr 6;77(13):1644-55. https://doi.org/10.1016/j.jacc.2021.02.023.
Das BB. COVID-19 and Pulmonary Hypertension in Children: What Do We Know So Far? Medicina (Kaunas). 2020 Dec 19;56(12):716. https://doi.org/10.3390/medicina56120716.
Farmakis I, Giannakoulas G. Management of COVID-19 in Patients with Pulmonary Arterial Hypertension. Heart Fail Clin. 2023 Jan;19(1):107–14. https://doi.org/10.1016/j.hfc.2022.07.003
Hinojosa W, Cristo-Ropero MJ, Cruz-Utrilla A, Segura de la Cal T, López-Medrano F, Salguero-Bodes R, Pérez-Olivares C, Navarro B, Ochoa N, Arribas Ynsurriaga F, Escribano-Subias P. The impact of COVID-19 pandemic on pulmonary hypertension: What have we learned? Pulm Circ. 2022 Oct 1;12(4):e12142. https://doi.org/10.1002/pul2.12142.
Huang Q, Jackson S, Derakhshan S, Lee L, Pham E, Jackson A, Cutter SL. Urban-rural differences in COVID-19 exposures and outcomes in the South: A preliminary analysis of South Carolina. PLoS One. 2021 Feb 3;16(2):e0246548. https://doi.org/10.1371/journal.pone.0246548.
Jackson SL, Derakhshan S, Blackwood L, Lee L, Huang Q, Habets M, Cutter SL. Spatial Disparities of COVID-19 Cases and Fatalities in United States Counties. Int J Environ Res Public Health. 2021 Aug 4;18(16):8259. https://doi.org/10.3390/ijerph18168259.
Kang M, Hart CM, Kempker JA, Veeraraghavan S, Trammell AW. Pulmonary hypertension mortality trends in United States 1999-2019. Ann Epidemiol. 2022 Nov;75:47-52. https://doi.org/10.1016/j.annepidem.2022.09.001. Epub 2022 Sep 9.
Lee JD, Burger CD, Delossantos GB, Grinnan D, Ralph DD, Rayner SG, Ryan JJ, Safdar Z, Ventetuolo CE, Zamanian RT, Leary PJ. A Survey-based Estimate of COVID-19 Incidence and Outcomes among Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension and Impact on the Process of Care. Ann Am Thorac Soc. 2020 Dec;17(12):1576-82. https://doi.org/10.1513/AnnalsATS.202005-521OC.
Mamzer A, Waligora M, Kopec G, Ptaszynska-Kopczynska K, Kurzyna M, Darocha S, Florczyk M, Mroczek E, Mularek-Kubzdela T, Smukowska-Gorynia A, Wrotynski M, Chrzanowski L, Dzikowska-Diduch O, Perzanowska-Brzeszkiewicz K, Pruszczyk P, Skoczylas I, Lewicka E, Blaszczak P, Karasek D, Kusmierczyk-Droszcz B, Mizia-Stec K, Kaminski K, Jachec W, Peregud-Pogorzelska M, Doboszynska A, Gasior Z, Tomaszewski M, Pawlak A, Zablocka W, Ryczek R, Widejko-Pietkiewicz K, Kasprzak JD. Impact of the COVID-19 Pandemic on Pulmonary Hypertension Patients: Insights from the BNP-PL National Database. Int J Environ Res Public Health. 2022 Jul 10;19(14):8423. https://doi.org/10.3390/ijerph19148423.
Montani D, Certain MC, Weatherald J, Jaïs X, Bulifon S, Noel-Savina E, Nieves A, Renard S, Traclet J, Bouvaist H, Riou M, de Groote P, Moceri P, Bertoletti L, Favrolt N, Guillaumot A, Jutant EM, Beurnier A, Boucly A, Ebstein N, Jevnikar M, Pichon J, Keddache S, Preda M, Roche A, Solinas S, Seferian A, Reynaud-Gaubert M, Cottin V, Savale L, Humbert M, Sitbon O; French PH Network PULMOTENSION Investigators. COVID-19 in Patients with Pulmonary Hypertension: A National Prospective Cohort Study. Am J Respir Crit Care Med. 2022 Sep 1;206(5):573-83. https://doi.org/10.1164/rccm.202112-2761OC.
Mishra A, Lal A, Sahu KK, George AA, Martin K, Sargent J. An Update on Pulmonary Hypertension in Coronavirus Disease-19 (COVID-19). Acta Biomed. 2020 Nov 10;91(4):e2020155. https://doi.org/10.23750/abm.v91i4.10698.
Mohammadi A, Balan I, Yadav S, Matos WF, Kharawala A, Gaddam M, Sarabia N, Koneru SC, Suddapalli SK, Marzban S. Post-COVID-19 Pulmonary Fibrosis. Cureus. 2022 Mar 2;14(3):e22770. https://doi.org/10.7759/cureus.22770.
Morales-Demori R, Mallory GB, Chartan C, Coleman R, Ruiz F, Villafranco N, Whalen E, Varghese N. Outcomes of COVID-19 infection in pediatric pulmonary hypertension: A single-center experience. Pediatr Pulmonol. 2021 Dec;56(12):3960-5. https://doi.org/10.1002/ppul.25650.
Norderfeldt J, Liliequist A, Frostell C, Adding C, Agvald P, Eriksson M, Lönnqvist PA. Acute pulmonary hypertension and short-term outcomes in severe Covid-19 patients needing intensive care. Acta Anaesthesiol Scand. 2021 Jul;65(6):761-9. https://doi.org/10.1111/aas.13819.
Nuche J, Pérez-Olivares C, Segura de la Cal T, Jiménez López-Guarch C, Arribas Ynsaurriaga F, Escribano Subías P. Clinical course of COVID-19 in pulmonary arterial hypertension patients. Rev Esp Cardiol (Engl Ed). 2020 Sep;73(9):775-8. https://doi.org/10.1016/j.rec.2020.05.015.
Pecoraro F, Luzi D. Open Data Resources on COVID-19 in Six European Countries: Issues and Opportunities. Int J Environ Res Public Health. 2021 Oct 6;18(19):10496. https://doi.org/10.3390/ijerph181910496.
Ruopp NF, Cockrill BA. Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review. JAMA. 2022 Apr 12;327(14):1379-91. https://doi.org/10.1001/jama.2022.4402.
Ryan JJ, Melendres-Groves L, Zamanian RT, Oudiz RJ, Chakinala M, Rosenzweig EB, Gomberg-Maitland M. Care of patients with pulmonary arterial hypertension during the coronavirus (COVID-19) pandemic. Pulm Circ. 2020 Apr 29;10(2):2045894020920153. https://doi.org/10.1177/2045894020920153.
Wats K, Rodriguez D, Prins KW, Sadiq A, Fogel J, Goldberger M, Moskovits M, Tootkaboni MP, Shani J, Jacob J. Association of right ventricular dysfunction and pulmonary hypertension with adverse 30-day outcomes in COVID-19 patients. Pulm Circ. 2021 Apr 19;11(2): 20458940211007040. https://doi.org/10.1177/20458940211007040.
https://coronavirus.rbc.ua/ukr/news/ukraine-2021-godu-tret-vyrosla-smertnost-1618836438.html